الفهرس 
Title : A pharmaceutical study on utilizing different nanovesicular carriers for the delivery of a certain drug
ContentsOnly 14 pages are availabe for public view
 |  | from | 256 |  |  |
| | | from | 256 | | |
Abstract
Transdermal drug delivery system (TDDS) is self-contained dosage form which can deliver the drug across the skin at predetermined rate to obtain therapeutic levels systemically. TDDS, compared with oral route, can reduce the load placed on the liver and digestive tract after oral administration and avoid the first pass effect and the gastro-intestinal degradation as well as side effects associated with some orally administrated medications. Furthermore, TDDS is mainly conductive for treatment of chronic diseases such as osteoarthritis (OA) which require treatment over extended duration as it provides uniform plasma levels of the drug by delivering it at a controlled and predetermined rate which could reduce the dosing frequency and side effects and consequently increase the patient compliance and adherence to dosage regimen. Furthermore, the high accessibility of skin as well as its relatively large surface area available for drug absorption is one of the most outstanding advantages of TDDS compared with conventional dosage forms. Diacerein (DCN) is one of the very recently introduced structural modifying osteoarthritis drugs (SMOADs). It selectively inhibits interleukins-1Ý L-1Ý) in human monocytes with consequent inhibition of nitric oxide (NO) production that has a significant role in cartilage degeneration. Hence, it aims at not only managing the symptoms of OA but also significantly affecting joints structure and consequently retarding disease progression and consequences. Being a BCS class II drug, DCN is slightly soluble in water (3.197 mg/L) with consequent erratic absorption profile. The remaining unabsorbed drug in colon induces laxative effect by stimulating prostaglandins (PGs) and acetylcholine release